JOURNEY
Through years of development, our team has built a comprehensive oncology portfolio that covers the full cycle of cancer management, addressing needs and challenges from early screening, diagnosis & monitoring, and biopharma development services. While continuously carrying out scientific and technological innovation, we efficiently transform these breakthroughs into clinical applications, which have served tens of thousands of patients, and dozens of scientific research institutions and pharmaceutical enterprises across China. See our journey below.
July
Established the Genetron Health Brand.
LABORATORY
Beijing laboratory is established.
January
Genetron Health Launches Oncology Diagnostics and Monitoring Platform.
February
LABORATORY
Laboratories in Shanghai and Chongqing are established.
January
Genetron Health Launches Biopharma Services Platform.
May
August
November
January
Genetron Health Launches Early Cancer Screening Platform.
March
April
Genetron Health's core technology "One-Step Seq Method" receives IP patent in China.
November
NGS Platform GENETRON S5 is approved to go to market in China.
Auto sample loading system GENETRON Chef is approved to go to market in China.
Genetron joins hands with iKang Group to create a new chapter in the prevention and treatment of liver cancer.
LABORATORY
Guangzhou laboratory is established.
January
Gene sequencer GENETRON S2000 is approved to go to market in China.
8-gene Lung Cancer Assay is approved to go to market in China.
March
Contributes to China's first 'NGS Clinical Application Standards' .
JUNE
JUNE
Listed on Nasdaq With Ticker Symbol GTH
August
Genetron Health becomes the only company to participate in China's Early Cancer National R&D Projects covering three different cancer varieties (liver, lung, digestive tract) .
September
Genetron Health receives U.S. FDA Breakthrough Device designation for its blood-based NGS test, HCCscreen.
November
Joined the "Liver Cancer Early Screening Comprehensive Prevention" public health initiative.
December
Genetron Health establishes various partnerships with AstraZeneca, Bayer, CStone Pharma, Novartis, and others.
January
Genetron Health begins strategic partnership with Chia Tai Tianqing (CTTQ) Pharmaceutical Group.
March
Genetron Health releases new prospective cohort study data of HCCscreen for early liver cancer screening.
July
Genetron Health receives CE Mark for 8-Gene Lung Cancer Assay.
August
Genetron Health receives full marks under the NCCL external quality assessment of NGS-based comprehensive genomic profiling for solid tumors, ranking first among the 63 laboratories nationwide.
November
Genetron Health’s early precision lung cancer diagnosis and treatment project, a joint initiative with the West China Hospital of Sichuan University, won the second prize of China’s National Science and Technology Progress Award.
November
Genetron Health signed a collaboration agreement with AstraZeneca R&D China for the joint development in China of NGS-based tumor-informed (personalized) MRD tests for various solid tumor types.
November
Genetron Health’s liver cancer screening results and technology findings are included in the expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma – submitted by the Infectious Disease Prevention and Control Division of the Chinese Preventive Medicine Association.
November
Genetron Health’s multi-gene mutation detection kit Onco PanScan obtains CE Mark.
LABORATORY
Laboratory in Maryland is established
February
March
April
June
Genetron Health receives CE Mark for its FusionScan Plus Kit for human multi-genes.
Genetron Health receives CAP Accreditation for its Maryland Laboratory.